Grace Therapeutics Reports FDA Type A Meeting Minutes, Updates NDA Path

What Happened

• Grace Therapeutics, Inc. filed a Form 8‑K on July 28, 2026 announcing receipt of U.S. FDA meeting minutes from a Type A meeting held to discuss the Complete Response Letter (CRL) the company received on April 23, 2026 for its GTx‑104 new drug application (NDA).
• On the same date, the company updated its corporate presentation (Late Summer 2026) to reflect the path to NDA resubmission following the Type A meeting. A press release and the updated presentation were furnished as exhibits to the 8‑K.

Key Details

• Filing date: July 28, 2026 (Form 8‑K, Item 8.01).
• Product: GTx‑104 NDA; original Complete Response Letter issued April 23, 2026.
• Company actions: received FDA Type A meeting minutes and updated investor/corporate presentation to show resubmission plan.
• Exhibits filed: Press release (Exhibit 99.1) and updated corporate presentation (Exhibit 99.2).

Why It Matters

• This is a regulatory‑process update: receipt of Type A meeting minutes means the company and FDA have documented next steps after the CRL, and management has refreshed its public presentation to reflect the resubmission path. For investors, it signals progress in the regulatory dialogue for GTx‑104 but is not an approval — it documents the plan toward an NDA resubmission and may clarify timing or required actions.